Pierre Fabre Pharmaceuticals Secures FDA Type A Meeting
SECAUCUS, N.J. — March 12, 2026 Pierre Fabre Pharmaceuticals announced that the U.S. Food and Drug Administration has agreed...
FDA Type A meeting
Unicycive Therapeutics to Resubmit OLC NDA After FDA Type A Meeting
Los Altos, California, October 28, 2025 — Unicycive Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for kidney disease,...